Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Anxiety Disorders, Depressive Disorders
Phase NA
Enrollment 144
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will consist in a randomized controlled clinical trial (RCT) to test the efficacy of a blended group transversal protocol (BLGr-TP) compared to a face-to-face group transversal protocol (FFGr-TP). The main aims of the study are the following: * To analyze the differential efficacy of the BLGr-TP versus the FFGr-TP for the treatment of emotional disorders in aspects of clinical measures, as well as in terms of retention and dropout rate and adherence. * To analyze the differential acceptability of the BLGr-TP versus the FFGr-TP for the treatment of emotional disorders. In addition, it is intended to carry out a study of mediators and moderators of the efficacy of both interventions. The established hypotheses in relation to the main goals are: * Both treatment modalities (FFGr-TP and BLGr-TP) will achieve improvements in the symptoms of emotional disorders, reflected in the scores of the clinical measures. * The BLGr-TP will show equivalent efficacy to the FFGr-TP. * The BLGr-TP will show an acceptability comparable to the face-to-face protocol. Both modalities will be well valued by the participants. * In both treatment modalities, the changes achieved are expected to be maintained over time (3, 6 and 12 months).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Blended group transversal protocol (BLGr-TP) — It will consist in the administration of a transdiagnostic treatment protocol composed by 16 modules focused on regulating both negative and positive affect. The intervention will be administered over a 16-week period. Face-to-face group sessions will be combined with autonomous work of patients through a web platform where they will find the contents of the program. The groups will have 6-10 patients, who will attend a total of 8 face-to-face sessions of 2 hours long each one. The online part of the treatment (self-applied Online Transversal Protocol) will consist in working the contents exposed in the face-to-face sessions during between-sessions period (2 weeks). It is an interactive program with multimedia elements (videos, images,…) that allows people to perform the modules from home and at their own pace. In addition, the program is characterized by its ease of use, presenting an agile navigation.
  • Behavioral: Face-to-face group transversal protocol (FFGr-TP) — It will consist in the administration of the transdiagnostic treatment protocol through the 16 modules focused on regulating both negative and positive affect. The intervention will be carried out in face-to-face group format and it will be administered during a 16-week period. The groups will have between 6 to 10 patients, who will attend a total of 16 face-to-face sessions of 2 hours long each one. During between-sessions period (1 week), patients will work the content of the modules exposed in the face-to-face sessions through tasks for home (traditional paper format).

Primary Outcomes

  • Change in the Overall Anxiety Severity and Impairment Scale (OASIS) (Campbell-Sills et al., 2009; González-Robles et al., 2018) at pre-treatment, post-treatment, and at 3-, 6- and 12-month follow-up. (Pre-treatment, post-modules (throughout the treatment), post-treatment (4 months), follow-up (7, 10 and 16 months))
  • Change in the Overall Depression Severity and Impairment Scale (ODSIS) (Bentley et al., 2014; Mira et al., 2019) at pre-treatment, post-treatment, and at 3-, 6- and 12-month follow-up. (Pre-treatment, post-modules (throughout the treatment), post-treatment (4 months), follow-up (7, 10 and 16 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-23
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 144 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitat Jaume I
Principal Investigators:
  • Amanda Díaz-García, Dr. (PRINCIPAL_INVESTIGATOR) - University of Zaragoza, Teruel Campus
  • Noelia Jiménez-Orenga, PhD student (PRINCIPAL_INVESTIGATOR) - Jaume I University, Castellón, Spain
  • Juana María Bretón-López, Dr. (PRINCIPAL_INVESTIGATOR) - Jaume I University, Castellón, Spain
Contact Information
Study Contact:
Juana María Bretón-López, Dr.
+34 964387642
breton@uji.es
Azucena García-Palacios, Dr.
+34 964387640
azucena@uji.es
Juana Bretón-López, Dr.
+34 964387642
breton@uji.es
Jaume I University, Castellón, Spain
Interventions
  • Behavioral: Blended group transversal protocol (BLGr-TP) — It will consist in the administration of a transdiagnostic treatment protocol composed by 16 modules focused on regulating both negative and positive affect. The intervention will be administered over a 16-week period. Face-to-face group sessions will be combined with autonomous work of patients through a web platform where they will find the contents of the program. The groups will have 6-10 patients, who will attend a total of 8 face-to-face sessions of 2 hours long each one. The online part of the treatment (self-applied Online Transversal Protocol) will consist in working the contents exposed in the face-to-face sessions during between-sessions period (2 weeks). It is an interactive program with multimedia elements (videos, images,…) that allows people to perform the modules from home and at their own pace. In addition, the program is characterized by its ease of use, presenting an agile navigation.
  • Behavioral: Face-to-face group transversal protocol (FFGr-TP) — It will consist in the administration of the transdiagnostic treatment protocol through the 16 modules focused on regulating both negative and positive affect. The intervention will be carried out in face-to-face group format and it will be administered during a 16-week period. The groups will have between 6 to 10 patients, who will attend a total of 16 face-to-face sessions of 2 hours long each one. During between-sessions period (1 week), patients will work the content of the modules exposed in the face-to-face sessions through tasks for home (traditional paper format).
Study Locations (1 sites)
Jaume I University, Castellón, Spain, Castellon, Castellón 12071 Spain
Eligibility Criteria
Inclusion Criteria: * Being 18 years old or more. * DSM-5 (APA, 1013) diagnostic criteria for emotional disorder (panic disorder, agoraphobia, social anxiety disorder, generalized anxiety disorder, major depressive disorder, dysthymia, obsessive-compulsive disorder, non-specified anxiety disorder, non-specified depressive disorder). * Good understanding of Spanish. * Access to the Internet and email address. * Informed consent to participate. Exclusion Criteria: * Diagnosis of a severe mental disorder (psychotic disorder, bipolar disorder, substance and/or alcohol dependence). * High risk of suicide. * Having a serious medical illness or other condition that prevents treatment from being carried out. * Receiving another psychological treatment during the study period. * Changes and/or increases in pharmacological treatment during the study period (a decrease is accepted).
Conditions Arterial Hypertension
Phase NA
Enrollment 80
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Renal denervation is a new method to lower blood pressure (BP) in hypertensive patients by reducing the impact of sympathetic nervous system. Its efficacy has been demonstrated in resistant hypertension and in lowering BP in essential hypertension as compared to a sham procedure in untreated hypertensive patients. This procedure is safe without any serious adverse events. However its effects during pregnancy are unknown. Normal pregnancy is associated with an increase of sympathetic activity at rest and upon cardiovascular reflexes stimulation which returns to baseline after delivery. These changes maintain optimal utero placental blood flow. But excessive stimulation of sympathetic activity may play a role in preeclampsia. Drugs that may affect the sympathetic nervous system are considered as safe in pregnant women. So there are reasonable evidence that renal denervation performed before pregnancy should not have deleterious effects for the fetus. The efficiency of renal denervation being greater in young patient and in women, a greater proportion of BP normalization can be expected in this population of young women .

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Double

Interventions / Regimen

  • Procedure: Arteriography and renal denervation — Diagnostic renal Arteriography - Randomization - Renal denervation
  • Procedure: Arteriography without renal denervation — Diagnostic renal Arteriography - Randomization

Primary Outcomes

  • Normalization of 24h blood pressure (at Day 100)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-01-31
Completion: 2028-11-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Bordeaux
Principal Investigators:
  • Philippe GOSSE, MD (STUDY_DIRECTOR) - University Hospital, Bordeaux
Contact Information
Study Contact:
Philippe GOSSE, MD
05 56 79 58 89
philippe.gosse@chu-bordeaux.fr
Julie GAUDISSARD
05 57 82 08 01
julie.gaudissard@chu-bordeaux.fr
Philippe GOSSE, MD
05 56 79 58 89
philippe.gosse@chu-bordeaux.fr
CHU de Bordeaux - Hôpital Saint-André
Interventions
  • Procedure: Arteriography and renal denervation — Diagnostic renal Arteriography - Randomization - Renal denervation
  • Procedure: Arteriography without renal denervation — Diagnostic renal Arteriography - Randomization
Study Locations (6 sites)
CHU de Bordeaux - Hôpital Saint-André, Bordeaux, France
CHU Grenoble-Alpes, Grenoble, 38043 Cedex 9 France
CHRU de LILLE - Hôpital Cardiologique, Lille, 59037 France
CHU de Nantes - Hôpital Laennec, Nantes, 44093 cedex 1 France
APHP - Hôpital Européen Georges-Pompidou, Paris, 75015 France
CHU de TOULOUSE - Hôpital Rangueil, Toulouse, 31059 Cedex 9 France
Eligibility Criteria
Inclusion Criteria: * ≥ 18 years and ≤ 40 years * Free, informed, written consent signed by the participant and the investigating physician (no later than the day of inclusion and before any examination required by the research) * Not pregnant but planning to be pregnant in the near future (\<2 years) * Patient using effective contraception, preferably micro-progestational, during the screening phase and the two-month post-procedure follow-up * Essential hypertension confirmed and documented by a previous complete search * Hypertension treated by 0-2 antihypertensive treatment(s) in a stable manner for at least 4 weeks and whose clinical BP measured in the sitting position during consultation is ≤ 180/110mmHg at the selection visit (D0), * Person able to understand and agree to follow all study procedures * Person who is affiliated or beneficiary of a social security plan Non-Inclusion Criteria: * Males of any age * Females whose age is \<18 years or \>40 * Orthostatic hypotension * Hypertension from secondary causes (other than sleep apnea) * Documented contraindication or proven severe allergy to iodinated contrast * Contraindication to use anticoagulants * Renal insufficiency with GFR estimated at \< 60ml/min/1.73m² * Antihypertensive treatment with more than two active ingredients * Type 1 diabetes or uncontrolled type II diabetes (plasma HbA1c level ≥ 9%) * History of chronic inflammatory bowel disease such as Crohn's disease or ulcerative colitis * Brachial circumference \> 40 cm * Any history of a cerebrovascular event (stroke, transient ischemic attack) * Any history of a serious cardiovascular event (myocardial infarction, acute heart failure requiring hospitalization, coronary artery bypass surgery) * Proven and confirmed episodes of stable or unstable angina in the 12 months preceding consent * Proven history of persistent or permanent atrial fibrillation * Presence of an active implantable medical device (e.g. neuromodulator/spinal modulator, baroreflex stimulator, ...) * Oxygen therapy or permanent ventilation other than CPAP for sleep apnea * Primary pulmonary hypertension * Limited life expectancy (\< 1 year) * Unresolved history of drug or alcohol abuse * Not have sufficient ability to understand or follow instructions * In the investigator's opinion she is unlikely to be willing or able to comply with the requirements of the study protocol or participation in the study will involve confounding factors in the analysis of the data * Participation in another trial of an investigational drug or device (participation in a non-interventional study is tolerated) * Pregnant or nursing mother * Person unable to give informed consent * Person deprived of liberty by judicial or administrative decision * Adults under legal protection Exclusion Criteria: * BP ≤ 135/85 mmHg and ≥ 160/100 mmHg (ABPM) after 4 weeks washout/run-in period. * Renal arterial anatomy not compatible with renal denervation confirmed by a good quality renal artery angioscan performed within one year prior to consent. * Patient without at least one artery on each side that can be treated with 2 or more ablations, * Renal artery anatomy: * Main renal artery diameter \< 3.0 mm and \> 8 mm * Main renal artery length \< 20 mm * A single functioning kidney (low differentiation or small kidney) * Kidney tumors presence * Renal arterial aneurysm presence * Pre-existing renal stent or history of renal artery angioplasty * Pre-existing aortic stent or history of aortic aneurysm * Prior renal denervation procedure * Fibromuscular dysplasia of the renal arteries * Presence of renal artery stenosis of any origin ≥ 30% * Presence of iliac/femoral artery calcification or stenosis precluding insertion of the Paradise Catheter * Infection within 7 days of the procedure

Dosing rTMS for Depression Post-SCI

NCT05553353
Recruiting
Conditions Spinal Cord Injuries, Depression, Depres...
Phase NA
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Depression is a leading cause of disability worldwide and is more commonly seen in individual's post-spinal cord injury (SCI) than in the general population. Depression post-SCI impacts an individuals' quality of life and recovery. It has been reported that among Veterans with an SCI, those without depression live longer than those with depression. Thus, depression must be treated appropriately. Repetitive transcranial magnetic stimulation (rTMS) is an FDA-approved treatment for depression, but dosing is based on a motor response or movement in the thumb. Over half of individuals with SCI have some degree of arm or hand impairment, so these individuals might not be eligible for rTMS, or they may receive the wrong dose. This study proposes clinical trial in individuals with depression post-SCI to assess the anti-depressant effect of a novel technique to dose rTMS that does not require a motor response in the thumb. By gaining a better understanding of the application of rTMS for depression post-SCI, the investigators aim to advance the rehabilitative care of Veterans.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: repetitive transcranial magnetic stimulation--Active — Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. An active coil will be used to administer the active rTMS.
  • Device: repetitive transcranial magnetic stimulation--Sham — Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. A sham coil will be used to administer the sham rTMS.

Primary Outcomes

  • Change from baseline in Hamilton Depression Rating Scale-17 (HAM-D17) score immediately post-intervention (Baseline; Following Week 2 of 6-week intervention Following Week 4 of 6-week intervention; Immediately post-intervention; 12-weeks post-intervention; 24-weeks post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-31
Completion: 2027-10-29
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Principal Investigators:
  • Catherine J VanDerwerker, PhD DPT PT (PRINCIPAL_INVESTIGATOR) - Ralph H. Johnson VA Medical Center, Charleston, SC
Contact Information
Study Contact:
Catherine J VanDerwerker, PhD DPT PT
(843) 792-5047
catherine.vanderwerker@va.gov
Sarah A Jackson, BA MA
(843) 789-6700
sarah.jackson@va.gov
Catherine J VanDerwerker, PhD DPT PT
843-792-5047
catherine.vanderwerker@va.gov
Ralph H. Johnson VA Medical Center, Charleston, SC
Interventions
  • Device: repetitive transcranial magnetic stimulation--Active — Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. An active coil will be used to administer the active rTMS.
  • Device: repetitive transcranial magnetic stimulation--Sham — Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. A sham coil will be used to administer the sham rTMS.
Study Locations (1 sites)
Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina 29401-5703 United States
Eligibility Criteria
Inclusion Criteria: * cervical or thoracic spinal cord injury at least 6 months prior with AIS A, B, C, or D; * 18 - 60 years of age; * major depressive disorder, as identified by Structured Clinical Interview for DSM-V; * Hamilton Depression Rating Scale-17 score \> 18; * not taking antidepressant medications or no change in doses of psychotropic medication(s) for at least 4 weeks before the study (6 weeks if newly initiated medication) Exclusion Criteria: * concomitant neurologic diseases/disorders or dementia; * cognitive impairment (Montreal Cognitive Assessment \<17); * history of psychosis or other Axis I disorder that is primary; * positive screen for bipolar disorder through the Mini-International Neuropsychiatric Interview; * history of claustrophobia; * life expectancy \<1 year; * electronic or metallic implants (i.e., metal in the head, cochlear implant, or pacemaker; * history of seizures or currently prescribed anti-seizure medications; * taking medication that increases the risk of seizures; * pregnancy as identified through a positive urine pregnancy test; * Hamilton Depression Rating Scale-17 question #3 regarding suicide: \>2 or suicide attempt within the previous two years; * inability to (University of California, San Diego Brief Assessment of Capacity to Consent) or declined to give informed consent.
Conditions Breast Cancer Female, Psychological Dist...
Phase PHASE2
Enrollment 452
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Many breast cancer survivors (estimated 70% in some studies) experience clinically significant depression and/or anxiety in the months and years after finishing cancer treatments. This research will build on the rigor of prior research to reduce breast cancer survivor depression and anxiety with a compassion meditation intervention called CBCT (Cognitively-Based Compassion Training) for online synchronous delivery that is also inclusive of informal caregivers (i.e., adult family members who live with and typically provide half the care for survivors, aka supportive partners).

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Cognitively-Based Compassion Training for Survivors — CBCT-S is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-S will be administered to breast cancer survivors and will not including supportive partners. Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance Module 2 (Week 2) Developing Stable and Clear Attention Module 3 (Week 3): Enhancing Self Awareness Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering. Module 6(Week 6): Expanding our Circle of Concern Module 7 (Week 7): Deepening Gratitude and Tenderness Module 8 (Week 8): Harnessing the Power of Compassion
  • Behavioral: Cognitively-Based Compassion Training for Dyads — CBCT-D is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-D will be administered to breast cancer survivors and supportive partners together. Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance Module 2 (Week 2) Developing Stable and Clear Attention Module 3 (Week 3): Enhancing Self Awareness Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering. Module 6(Week 6): Expanding our Circle of Concern Module 7 (Week 7): Deepening Gratitude and Tenderness Module 8 (Week 8): Harnessing the Power of Compassion
  • Behavioral: Health Education — HE focuses on topics relevant to health and cancer, but is also intended for individuals who are not cancer survivors themselves. HE will be administered to both breast cancer survivors and supportive partners together. Module I (Week 1): Cancer Advocacy. Module II (Week 2): Health Through the Lifespan. Module III (Week 3): Nutrition. Module III (Week 4): Nutrition. Module IV (Week 5): Physical Activity. Module V (Week 6): Sleep. Module VI (Week 7): Stress. Module VII (Week 8): Mental Health and Social Support.

Primary Outcomes

  • Change in depression features (Change from baseline depression to 8 weeks after the start of intervention)
  • Change in anxiety features (Change from baseline anxiety to 8 weeks after the start of intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-03-20
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 452 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Arizona
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Thaddeus Pace, PhD (PRINCIPAL_INVESTIGATOR) - University of Arizona
Contact Information
Study Contact:
Tausif Chowdhury
520-621-8809
tausifbhai@arizona.edu
Tausif Chowdhury
520-621-8809
tausifbhai@arizona.edu
University of Arizona
Interventions
  • Behavioral: Cognitively-Based Compassion Training for Survivors — CBCT-S is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-S will be administered to breast cancer survivors and will not including supportive partners. Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance Module 2 (Week 2) Developing Stable and Clear Attention Module 3 (Week 3): Enhancing Self Awareness Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering. Module 6(Week 6): Expanding our Circle of Concern Module 7 (Week 7): Deepening Gratitude and Tenderness Module 8 (Week 8): Harnessing the Power of Compassion
  • Behavioral: Cognitively-Based Compassion Training for Dyads — CBCT-D is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-D will be administered to breast cancer survivors and supportive partners together. Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance Module 2 (Week 2) Developing Stable and Clear Attention Module 3 (Week 3): Enhancing Self Awareness Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering. Module 6(Week 6): Expanding our Circle of Concern Module 7 (Week 7): Deepening Gratitude and Tenderness Module 8 (Week 8): Harnessing the Power of Compassion
  • Behavioral: Health Education — HE focuses on topics relevant to health and cancer, but is also intended for individuals who are not cancer survivors themselves. HE will be administered to both breast cancer survivors and supportive partners together. Module I (Week 1): Cancer Advocacy. Module II (Week 2): Health Through the Lifespan. Module III (Week 3): Nutrition. Module III (Week 4): Nutrition. Module IV (Week 5): Physical Activity. Module V (Week 6): Sleep. Module VI (Week 7): Stress. Module VII (Week 8): Mental Health and Social Support.
Study Locations (1 sites)
University of Arizona, Tucson, Arizona 85721 United States
Eligibility Criteria
Breast cancer survivors: Inclusion Criteria: * biological sex: woman * able to speak and understand English * have a diagnosis of a breast cancer * have completed primary curative cancer treatments (i.e., surgery, radiation, chemotherapy) except for hormonal therapies (e.g., aromatase inhibitors) or trastuzumab a minimum of 3 months and a maximum of 5 years before starting CBCT or the control * have a supportive partner (aka caregiver) who can participate with them Exclusion Criteria: * nursing home resident * have ongoing (1 or more meditation sessions per week) or past regular meditation experience in the last 4 years (i.e., more than two meditation sessions \[completed or attempted\] per year, either with a group or individually, to be evaluated by the Principal Investigator) Supportive partners (aka informal caregivers) Inclusion Criteria: * named by the survivor * live in the same household as the survivor * able to speak and understand English Exclusion Criteria: * have ongoing (1 or more meditation sessions per week) or past regular meditation experience in the last 4 years (i.e., more than two meditation sessions \[completed or attempted\] per year, either with a group or individually, to be evaluated by the Principal Investigator)
Conditions Treatment Resistant Depression
Phase PHASE2
Enrollment 72
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant depression when administered as monotherapy or as adjunctive therapy with defined SSRIs (citalopram, escitalopram, sertraline or fluoxetine).

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BPL-003 — Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)

Primary Outcomes

  • 1. To assess the safety and tolerability of single or multiple intranasal doses of BPL-003 in patients with treatment resistant depression (Baseline to 12 weeks post dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-02-10
Completion: 2026-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beckley Psytech Limited
Principal Investigators:
  • Kevin Craig, M.D. (STUDY_DIRECTOR) - Beckley Psytech Ltd
Contact Information
Study Contact:
Kevin Craig, M.D.
332-282-0507
clinicaltrials@ataibeckley.com
0800 917 7637
info@researchforyou.co.uk
MAC Clinical Research
Study Coordinator
+44 (0)20 8961 4130
REC@hmrlondon.com
Hammersmith Medicines Research
Interventions
  • Drug: BPL-003 — Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)
Study Locations (3 sites)
MAC Clinical Research, Liverpool, L34 1BH United Kingdom
Hammersmith Medicines Research, London, United Kingdom
King's College London, Clinical Trials Facility, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with Major Depressive Disorder. 2. Diagnosed with TRD defined as failure to respond to an adequate dose and duration of at least 2 pharmacological treatments in the past 5 years prior to screening, at least one of which is during the current episode. 3. Montgomery-Asberg Depression Rating Scale score ≥24 at Screening. 4. Clinical Global Impression - Severity ≥4 at Screening. 5. Willing and able to discontinue current pharmacological anti-depressant therapy. 6. On current stable dose of pharmacological antidepressant therapy limited to one of 4 SSRIs (Arm B), i.e. either citalopram, escitalopram, sertraline or fluoxetine. Exclusion Criteria: 1. Current or history of schizophrenia, psychotic disorder including psychotic depression, bipolar disorder, delusional disorder, schizoaffective disorder, or any other severe psychiatric disorder. 2. Current personality disorders. 3. First-degree family history of schizophrenia, bipolar disorder, delusional disorder, personality disorders or schizoaffective disorder. 4. Current alcohol or substance use disorder (other than caffeine or nicotine). 5. A participant who at any time, has been unresponsive to ketamine, esketamine, an adequate course of treatment with electroconvulsive therapy, or has received vagal nerve stimulation or deep brain stimulation. 6. Suicidal ideation with the intent to act or suicidal behaviour within the 12 months prior to the start of Screening or on Day 1 prior to dosing. 7. Suicide attempt and/or self-injurious behaviour within the last 12 months prior to Screening. 8. Uncontrolled medical conditions e.g. hypo/hyperthyroidism, diabetes, renal failure. 9. Seizure disorder or history of seizures (including febrile seizures). 10. Abnormal and clinically significant results on the physical examination, vital signs, electrocardiogram, or laboratory tests at Screening Baseline. 11. Any nasal obstruction, blockage, or symptoms of congestion at the time of dosing, that in the Investigator's opinion may interfere with administration of the study drug. 12. Currently receiving lithium, antipsychotics, serotonergic drugs (excluding the permitted SSRIs for arm B), psychostimulants, or any other prohibited medication. 13. Female patients who are pregnant or lactating, or of childbearing potential and not willing to use adequate forms of contraception. 14. Male patients who are sexually active and not willing to using adequate forms of contraception.
Conditions Depression Symptoms, Anxiety Symptoms
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In recent years, the number of people with symptoms of depression or anxiety are on the rise. The aims of the prospective randomized study are: (1) to examine the effects of Baduanjin breathing training on reducing symptoms of depression or anxiety, and (2) to explore the correlates between improvements of depression or anxiety symptom and changes of lung functions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Baduanjin — The Baduanjin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
  • Behavioral: Health education — Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.

Primary Outcomes

  • 17-item Hamilton Depression Rating Scale (Change from Baseline HAMD-17 at 16 weeks)
  • 14-item Hamilton Anxiety Rating Scale (Change from Baseline HAMA-14 at 16 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-07-01
Completion: 2027-07-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai University of Traditional Chinese Medicine
Collaborators: Shanghai Mental Health Center
Principal Investigators:
  • Xiaoting Zhao (STUDY_CHAIR) - Shanghai Qigong Research Institute
  • Ying Lu (PRINCIPAL_INVESTIGATOR) - Shanghai Qigong Research Institute
  • Jie Li (STUDY_DIRECTOR) - Shanghai University of Traditional Chinese Medicine
Contact Information
Study Contact:
Ying Lu, Master
02154240423
luwing_happy@163.com
Xiaoting Zhao
02154240423
zxt7410@163.com
Jie Li, doctor
02164383936
lijietcm@163.com
Shanghai Qigong Research Institute
Interventions
  • Behavioral: Baduanjin — The Baduanjin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
  • Behavioral: Health education — Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
Study Locations (1 sites)
Shanghai Qigong Research Institute, Shanghai, Shanghai Municipality 021 China
Eligibility Criteria
Inclusion Criteria: * Subject with depression or anxiety symptom diagnosed by ICD-10. * Depression 7≤HAMD-17≤29,anxiety 7≤HAMA-14≤29. * Subject has a clear mind and the ability to read, to talk and to communicate. * Subject agrees to participate in this study and sign to the informed consent. Exclusion Criteria: * Subject with bipolar disorder, psychotic disorder, organic mental disorder and cognitive disorder. * Subject with alcohol abuse, substance dependence and suicidal behavior in past-year. * Subject has severe somatic disease. * Subject is pregnant or lactating women.
Conditions Glaucoma, Cataract, Ophthalmological Dis...
Phase PHASE1, PHASE2
Enrollment 154
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Microneedle (MN) is a mimic of a hypodermic needle, composed of hundreds of micron-sized, out-of-plane protrusions, typically arranged in arrays on a patch that can be applied onto the skin. MN can be fabricated from a variety of materials, preferably biocompatible polymers. Maltose, a natural carbohydrate, is a safe and biocompatible product that can be fabricated into MNs that are biodegradable and soluble within several minutes. Besides, local anaesthetic agents such as lignocaine can be impregnated within the MN matrix, facilitating its transdermal delivery more efficiently which results in enhanced efficacy. So far, maltose MN efficacy in enhancing the transdermal drug delivery (TDD) of lignocaine and thus reducing the pain experienced by healthy patients requiring venepuncture prior to routine eye surgeries (phacoemulsification, trabeculectomy etc) has not been extensively studied. Hence, the objectives of this research are: 1) To evaluate the safety profile of lignocaine-embedded microneedle patch as a means of pain reduction in adult patients requiring routine vein-puncturing procedures; 2) To assess the pharmacokinetic (PK) parameters of lignocaine in the systemic circulation when the transdermal lignocaine delivery is enhanced through microneedle usage; 3) To compare the efficacy of lignocaine-embedded microneedle patch with standard 5% Eutectic Mixture of Local Anesthetics (EMLA) dermal patch for pain reduction during venepuncture procedure based on mean changes in VAS scores and skin algesimeter index (pharmacodynamic (PD) study).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Combination Product: Lignocaine-loaded maltose microneedle array patch — A biodegradable maltose microneedle array patch containing 12.5 mg lignocaine that will be applied on the participant's dorsal aspect of the hand for 30 minutes prior to venepuncture.
  • Drug: EMLA 5% patch — EMLA 5% cream applied on the dorsum of the participant's hand which will be subsequently covered with PVA-PET adhesive for 30 minutes prior to venepuncture

Primary Outcomes

  • Visual Analogue Score (VAS) (The measurements will be made at 1 minute after venepuncture which will be inserted following EMLA-impregnated microneedle patch or standard EMLA patch application])
  • Skin Conductance Algesimeter Index (The measurements will be made at 1 minute after venepuncture which will be inserted following EMLA-impregnated microneedle patch or standard EMLA patch application])
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-02-17
Completion: 2026-12-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 154 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universiti Kebangsaan Malaysia Medical Centre
Principal Investigators:
  • FOOK CHOE CHEAH, MD, PhD, MRCPCH (PRINCIPAL_INVESTIGATOR) - FACULTY OF MEDICINE, UNIVERSITI KEBANGSAAN MALAYSIA (UKM)
  • AZRUL AZLAN BIN HAMZAH, BSc, PhD (PRINCIPAL_INVESTIGATOR) - INSTITUTE OF MICROENGINEERING AND NANOELECTRONICS, UNIVERSITI KEBANGSAAN MALAYSIA
Contact Information
Study Contact:
MUHAMMAD IRFAN BIN ABDUL JALAL, MBChB BAO, PhD
+60172107299
irfan.abduljalal@ukm.edu.my
CHENSHEN LAM, MD, D.OPHTH
+6017-6051693
lamchenshen@ukm.edu.my
MUHAMMAD IRFAN BIN ABDUL JALAL, MBChB PhD
+60172107299
irfan.abduljalal@ukm.edu.my
Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia (Ukm Medical Centre)
Interventions
  • Combination Product: Lignocaine-loaded maltose microneedle array patch — A biodegradable maltose microneedle array patch containing 12.5 mg lignocaine that will be applied on the participant's dorsal aspect of the hand for 30 minutes prior to venepuncture.
  • Drug: EMLA 5% patch — EMLA 5% cream applied on the dorsum of the participant's hand which will be subsequently covered with PVA-PET adhesive for 30 minutes prior to venepuncture
Study Locations (1 sites)
Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia (Ukm Medical Centre), Kuala Lumpur, Kuala Lumpur 56000 Malaysia
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years old and above * Patients requiring venepuncture for blood investigations before ophthalmological procedures Exclusion Criteria: * Patient with a previous history of sensitization or allergy to lignocaine. * Patient with a previous history of allergy to materials used in the study i.e., plaster, electrodes, maltose, Polyvinyl Alcohol (PVA), and Polyethylene Terephthalate (PET) * Patient exposed to analgesic usage within 24 hours prior to the procedure * Generalized skin disorder/ rash * Agitated/ fretful / uncooperative patient * Uncommunicative/deaf/mute patients * Patients on hypnotics, or chronic pain relief medications * Patients with psychiatric conditions * Patients with hepatic impairment * Patients who are on CYP450 3A4, 3A5 or 1A2-inducing or inhibiting drugs (erythromycin, ciprofloxacin, amiodarone etc.) or pharmacotherapeutic agents that affect hepatic blood flow (metoprolol) since both may affect the metabolism of lignocaine * Failed first/single attempt at venepuncture after the application of the LEMAP or PET patch for control arm.
Conditions Wheezing, Asthma in Children
Phase PHASE2
Enrollment 65
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to compare soy isoflavones to placebo in children who at risk of asthma and have a genetic variation which results in them making more of a pro-inflammatory protein, plasminogen activator inhibitor-1. The main questions this trail seeks to answer is: will soy isoflavones decrease the proportion of infants with aT2 high endotype at the end of treatment, and secondarily decrease the number of wheezing episodes in these children when given in the first year of life. Participants will be asked to ingest soy isoflavone or placebo twice daily mixed into a liquid or puree vehicle for 7 months from randomization. There will be 3 mandatory in-person visits, and 6 virtual visits in the first year. There will also be 11 monthly questionnaires and 1 in person visit in the observation year. Participants will have 4 nasal swabs, 3 blood draws, and also provide 4 stool samples over the course of the study.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Soy isoflavone — Soy isoflavone supplement (Novasoy) that contains isoflavones (genistein, daidzein, glycetein) given at a dose of genistein aglycone equivalents to provide the genistein dosing of 22.6 mg/day for children aged 2-10 months, and 30.3 mg/day children aged 10-24 months
  • Drug: matching placebo — A matching placebo also administered twice daily.

Primary Outcomes

  • T2 endotype (From week 0 (randomization) to week 30 (end of treatment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-09-18
Completion: 2028-12-31
Eligibility
Age: 2 Months and older
Sex: ALL
Volunteers: true
Enrollment: 65 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rajesh Kumar
Collaborators: Northwestern University, University of South Florida, University of Colorado, Denver, National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigators:
  • Rajesh Kumar, MD (PRINCIPAL_INVESTIGATOR) - Ann & Robert H Lurie Children's Hospital of Chicago
Contact Information
Study Contact:
Sarah Godley, RN
312 227 6010
sgodley@luriechildrens.org
Rajesh Kumar, MD
312 227 6010
Ann and Robert H Lurie Childrens Hospital of Chicago
Rajesh Kumar, MD
Ann and Robert H Lurie Childrens Hospital of Chicago
Interventions
  • Drug: Soy isoflavone — Soy isoflavone supplement (Novasoy) that contains isoflavones (genistein, daidzein, glycetein) given at a dose of genistein aglycone equivalents to provide the genistein dosing of 22.6 mg/day for children aged 2-10 months, and 30.3 mg/day children aged 10-24 months
  • Drug: matching placebo — A matching placebo also administered twice daily.
Study Locations (2 sites)
Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois 60611 United States
Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611 United States
Eligibility Criteria
Inclusion Criteria: 1. Parent/guardian must be an adult (≥18 years of age) and able to understand and provide informed consent. 2. Age: Term infants (≥37 weeks gestational age) less than 12 months of age at recruitment 3. High risk of asthma: As determined by one or more of the following: 1. A history of uni- or bi-parental asthma with onset in childhood by parent self report, OR 2. Uni- or bi-parental asthma with onset after childhood along with the presence of one or more other comorbid atopic condition including allergic rhinitis, atopic dermatitis, or food allergy, OR 3. atopic dermatitis in the child determined by parent report of a physician diagnosis 4. Genotype: Either homozygous or heterozygous for the PAI-1 risk allele (i.e. 4G4G or 4G5G). 5. Have a primary place of residence in one of the pre-selected recruitment census tracts as outlined in the SIRA Manual of Operations (MOP). 1. Participants who do not live in the pre-selected census tracts but live within the Office of Management and Budget (OMB) defined Metropolitan Statistical Area and have publicly funded health insurance will qualify for inclusion. Exclusion Criteria: 1. 1\. Inability or unwillingness of a parent or guardian to give written informed consent or comply with study protocol. 2. Parents who will not include either a puree or some form of bottle feeding such that the infant would be able to take the investigational product in a puree or a liquid (expressed breast milk, supplemental formula, or a small amount of water). 3. Currently on a soy based formula. 4. Breastfeeding mothers who are taking soy supplements or soy enriched foods more than 2 times a week and will not stop this level of ingestion while breastfeeding. 5. On treatment for recurrent wheezing such as regular inhaled steroids. 6. The infant may not have the following specific contraindications: known congenital thyroid disease, or a history of estrogen sensitive clinically relevant mutations in the family (such as BRCA1). 7. Medication use 1. Maternal use of tamoxifen in pregnancy or if breastfeeding 2. Use of immunomodulatory medications such at methotrexate, mycophenolate, azathioprine, or other immunomodulatory agent in the mother if breastfeeding or in the infant. 8. Use of another investigational agent in the last 30 days prior to randomization. 9. Current, parent reported, diagnosis of mental illness or current, diagnosed or self-reported drug or alcohol abuse (in the primary caregiver) that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements. 10. Known allergy to soy protein (either by reported allergy or skin testing to soy prior to randomization) or reported allergy to NovaSoy, from which the investigational product is compounded. 11. The infant is currently participating in another asthma-related pharmaceutical study or intervention study or who have participated in another asthma-related pharmaceutical study or intervention study in the month prior to enrollment. 12. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study. 13. Infant requiring intubation prior to screening. 14. Infant requiring \> 3 hospitalizations for asthma symptoms/ wheezing illness prior to screening. 15. Infant requiring \> 3 five day bursts of oral steroid at least 14 days apart from each other prior to screening. 16. Any chronic condition requiring use of systemic corticosteroids or another immunomodulating agent at screening or before randomization, and during the course of the study. 17. Non-adherence: 1. Inability / unwillingness of the parents to induce the infant to swallow study medication 2. Unwillingness of the parents to allow the staff to perform baseline measurements 18. Living with a foster parent as a ward of the state. 19. Caregiver does not have access to a phone (needed for scheduling appointments or responding to questionnaires). 20. Plan(s) for the family to move from the area during the study period. 21. The infant's caretaker does not primarily speak English or Spanish. In order to be eligible to continue in the study following screening visit A (V1) , an individual must meet all of the following additional randomization criteria: 1. Must be ≥4 months and \<12 months of age at randomization 2. Must have either 4G/4G or 4G/5G genotype 3. Cannot have had a severe wheezing exacerbation requiring ICU admission between screening (V1) and randomization (V3) 4. Cannot have had more than two wheezing / "asthma" episodes (separated from each other by at least 14 days), each requiring at least a 5 day course of oral steroids in the time between screening visit A (V1) and randomization (V3).
Conditions Postpartum Complication, Maternal Hypert...
Phase PHASE3
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Oral Nifedipine — Administration of oral nifedipine to control postpartum hypertension.
  • Drug: Oral Labetalol — Administration of oral labetalol to control postpartum hypertension.

Primary Outcomes

  • Composite maternal morbidity (0-6 weeks following delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-05-08
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Loma Linda University
Contact Information
Study Contact:
Ashra Denise B Tugung, BSc
9096515580
atugung@llu.edu
Nikia Gray-Hutto, RN, CCRP
9095584000
nhutto@llu.edu
Ashra Tugung
atugung@llu.edu
Loma Linda University Health
Interventions
  • Drug: Oral Nifedipine — Administration of oral nifedipine to control postpartum hypertension.
  • Drug: Oral Labetalol — Administration of oral labetalol to control postpartum hypertension.
Study Locations (1 sites)
Loma Linda University Health, Loma Linda, California 92350 United States
Eligibility Criteria
Inclusion Criteria: * Female * Women who develop postpartum hypertension\* after delivery of the placenta or chronic hypertensive postpartum women who require medication for blood pressure control. * Postpartum hypertension requiring treatment are defined as systolic blood pressure greater than or equal to 140mmHg or diastolic blood pressure greater than or equal to 90mmHg on at least 2 occasions at least 4 hours apart, or systolic blood pressure greater than or equal to 160mmHg or diastolic blood pressure greater than 110mmHg sustained for more than 15 minutes. Exclusion Criteria: * History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema * Contraindication to either Nifedipine or Labetalol * HR \<60 or \>110 * Native language other than English or Spanish
Conditions Physical Activity, Sedentary Behavior, D...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The current project aims to design and implement an 8-week Virtual Reality Adventure Therapy Exergaming (V-RATE) intervention focused on women veterans. A randomized controlled trial using a repeated measure design with a 1-month follow-up assessment will be employed to examine effects on physical and mental health outcomes.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Virtual Reality-based physical activity intervention — The V-RATE intervention will be delivered through a 360-degree non-mobilized treadmill in a university clinical laboratory for 6-8-weeks (1-2 days/week, 30 minutes/session) totaling 6 sessions. The V-RATE program will be focused on creating a safe and immersive environment supportive of physical activity. The treadmill enables an individual can walk and run at self-paced speed, moving in 360-degrees (i.e., forwards, sideways, and backwards) without risk of falling. The core feature of the self-paced treadmill is a concave walking platform with an adjustable waist hardness that enables a safe, smooth, natural gait while adults with elevated BMI engage in an immersive walking and running motion. During the V-RATE intervention, participants will self-pace their locomotor action (walking/running/bending/ jumping) while they wear the VR headset and experience immersive VR adventure games using the Omniverse VR system.

Primary Outcomes

  • Change in depression from baseline to week 6-8 and one-month follow-up (Week 12) (Baseline, Week 6-8, Week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-09-07
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas at Arlington
Contact Information
Study Contact:
Donna L Schuman, PhD
18172723181
donna.schuman@uta.edu
Xiangli Gu, PhD
817-818-2106
xiangli.gu@uta.edu
Donna L Schuman, PhD
817-272-3181
donna.schuman@uta.edu
University of Texas at Arlington
Interventions
  • Device: Virtual Reality-based physical activity intervention — The V-RATE intervention will be delivered through a 360-degree non-mobilized treadmill in a university clinical laboratory for 6-8-weeks (1-2 days/week, 30 minutes/session) totaling 6 sessions. The V-RATE program will be focused on creating a safe and immersive environment supportive of physical activity. The treadmill enables an individual can walk and run at self-paced speed, moving in 360-degrees (i.e., forwards, sideways, and backwards) without risk of falling. The core feature of the self-paced treadmill is a concave walking platform with an adjustable waist hardness that enables a safe, smooth, natural gait while adults with elevated BMI engage in an immersive walking and running motion. During the V-RATE intervention, participants will self-pace their locomotor action (walking/running/bending/ jumping) while they wear the VR headset and experience immersive VR adventure games using the Omniverse VR system.
Study Locations (1 sites)
University of Texas at Arlington, Arlington, Texas 76019 United States
Eligibility Criteria
Inclusion Criteria: 1. Are between the ages of 18 and 45 2. Identify as a U.S. military veteran 4\. Normal vision (no colorblindness) Exclusion Criteria: 1. Unable to walk independently (e.g., use of any mobility assistive device such as brace, wheelchair, cane, crutch, walker, knee scooter) 2. Self-reported joint problem that limits mobility (e.g., arthritis or other condition that would prevent participation) or ongoing orthopedic injury 3. Self-reported pregnancy or suspicion of pregnancy 4. Self-reported motor disorder or impaired sense of motion or balance (such as Parkinsonism) 5. Self-reported color blindness 6. Self-reported neurological or cognitive disorder (e.g., TBI, history of seizure) 7. Self-reported cardiac surgery or any ongoing cardiovascular issues preventing participation or physical activity.
Conditions Depression, Posttraumatic Stress Disorde...
Phase NA
Enrollment 118
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Pregnant women in South Africa (SA) are at high risk of HIV acquisition. Pre-exposure prophylaxis (PrEP) use during pregnancy is both safe and effective in preventing HIV. However, posttraumatic stress (associated with intimate partner violence and/or other traumas) and depression negatively impact PrEP adherence among women in SA. Addressing posttraumatic stress and depression will likely improve PrEP adherence and persistence (i.e., sustained PrEP adherence over time) during pregnancy and breastfeeding, which are periods of dramatically increased HIV risk. The overarching goal of this proposal is to develop and test the feasibility and acceptability of a cognitive behavioral intervention that targets common underlying factors of posttraumatic stress and depression to improve PrEP adherence and persistence during pregnancy and the postpartum transition. The specific aims of the project are to (1) explore the mechanisms by which posttraumatic stress and depression impact PrEP adherence and persistence during pregnancy via qualitative interviews; (2) develop a brief PrEP adherence and persistence intervention (\~4 sessions) that reduces the negative impact of psychological mechanisms common to posttraumatic stress and depression on PrEP use, and builds behavioral skills to improve self-care; and (3) evaluate the feasibility, acceptability, and signals of preliminary efficacy of the intervention, which will be integrated into antenatal care, in a pilot randomized controlled trial. All data will be collected in the Midwife Obstetrics Unit (MOU) in Gugulethu, a peri-urban settlement and former township community outside of Cape Town, SA.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Brief CBT-Based Intervention — Aims 1 (n=30) and 2 (n=18) will inform the Aim 3 intervention. We anticipate that the intervention will be comprised of four treatment sessions. These sessions will likely target two pathways to PrEP adherence and persistence: (1) decreased withdrawal and avoidance and (2) behavioral skill building to increase self-care/health behaviors. To decrease withdrawal and avoidance, we will likely include CBT-based exercises that improve distress tolerance and coping. To help participants build new behavioral skills, we will likely incorporate behavioral activation and problem-solving. Behavioral activation is a CBT strategy that promotes scheduling activities that align with an individual's values, which will also break maladaptive patterns of withdrawal and avoidance. Problem-solving is an empirically-supported treatment for depression; training patients to problem-solve adaptively will help them "approach" PrEP use by navigating barriers.
  • Other: Enhanced Treatment as Usual — This is the control intervention. Participants will receive antenatal care as usual, which is monthly visits to the MOU, information about using PrEP during pregnancy (information sheet or pamphlet), and a psychological services referral.

Primary Outcomes

  • Feasibility of Intervention (This will be assessed at 2 months post-baseline)
  • Acceptability (This will be assessed at 2 months post-baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-17
Completion: 2027-07-30
Eligibility
Age: 15 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 118 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boston University Charles River Campus
Collaborators: University of Cape Town, National Institute of Mental Health (NIMH)
Principal Investigators:
  • Amelia Stanton, PhD (PRINCIPAL_INVESTIGATOR) - Boston University
Contact Information
Study Contact:
Amelia M Stanton, PhD
617-353-2580
stantona@bu.edu
Amelia M Stanton, PhD
617-353-2580
stantona@bu.edu
Boston University
Madison R Fertig, MA
617-358-1374
mrfertig@bu.edu
Boston University
Interventions
  • Behavioral: Brief CBT-Based Intervention — Aims 1 (n=30) and 2 (n=18) will inform the Aim 3 intervention. We anticipate that the intervention will be comprised of four treatment sessions. These sessions will likely target two pathways to PrEP adherence and persistence: (1) decreased withdrawal and avoidance and (2) behavioral skill building to increase self-care/health behaviors. To decrease withdrawal and avoidance, we will likely include CBT-based exercises that improve distress tolerance and coping. To help participants build new behavioral skills, we will likely incorporate behavioral activation and problem-solving. Behavioral activation is a CBT strategy that promotes scheduling activities that align with an individual's values, which will also break maladaptive patterns of withdrawal and avoidance. Problem-solving is an empirically-supported treatment for depression; training patients to problem-solve adaptively will help them "approach" PrEP use by navigating barriers.
  • Other: Enhanced Treatment as Usual — This is the control intervention. Participants will receive antenatal care as usual, which is monthly visits to the MOU, information about using PrEP during pregnancy (information sheet or pamphlet), and a psychological services referral.
Study Locations (2 sites)
Boston University, Boston, Massachusetts 02215 United States
Gugulethu Midwife Obstetric Unit (MOU), Cape Town, Western Cape 8001 South Africa
Eligibility Criteria
Inclusion Criteria: * For participants across all three aims are: * Female sex * Aged 15+ * Pregnant and presenting antenatal care at the Gugulethu MOU * HIV-negative * Recent PrEP initiation (\<1 month ago) or PrEP adherence challenges, either documented (\>2 weeks late to pick up PrEP refill) or self-reported * Moderate to severe symptoms of posttraumatic stress and/or depression (defined as a score of ≥31 on PTSD Checklist for DSM-5 (PCL-5) and/or a score of ≥13 on the Edinburgh Postnatal Depression Scale (EPDS). Cutoff scores may be adjusted by 3-5 points to facilitate recruitment. Exclusion Criteria: * There are no exclusion criteria with respect to parity or gravidity. * Participants who are unable to provide informed consent or assent in English or Xhosa * Have a significant psychiatric illness (e.g., active psychotic disorder or untreated bipolar disorder) that could interfere with participation will be excluded. Positive symptoms of active psychosis or mania will be assessed by the research assistants. They will be trained to identify delusions, hallucinations, disorganized or pressured speech, flight of ideas, and grandiosity as they speak to potential participants. * Potential participants will also be asked if they have any health conditions that make it difficult for them to travel to the clinic.
Conditions Race-related Stress, Depression, Anxiety...
Phase PHASE1, PHASE2
Enrollment 66
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black adolescents and young adults in coping with race related stress. The study will consist of a small, purposeful, non-randomized sample (N = 30) of clients enrolled into a 10-session Acceptance and Commitment Therapy group. The group will be offered as part of regular clinical care at the Division of Adolescent and Young Adult Medicine. Three consecutive groups will be run with approximately 8-10 participants in each group over the next year.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: ACT for SCD — Phase I Using a convenience sample, this study examines the feasibility and acceptability of a proposed 6-session ACT group intervention for Black youth with sickle cell disease (SCD), who experience compounded stress due to chronic illness and systemic inequities. A up to 11 youth and up to 11 parents/legal guardians will be enrolled in an ACT group offered via the Division of Adolescent and Young Adult Medicine. Participants will complete assessments at pre-, and post-intervention, and at a 3-month follow-up. Up to 5 of 11 parents/legal guardians and 5 of 11 youth (not required to be dyadic) will also be a part of the studies community advisory board (CAB) to ensure the intervention is culturally and developmentally responsive and grounded in community perspectives. Phase II Over the next 3 years this study will use a community-based participatory action research approach, extending and integrating feedback data collected in Phase I, to conduct a crossover waitlist-control trial.

Primary Outcomes

  • Total Score on Index of Race-Related Stress (IRRS)-Brief Version (12 weeks)
  • Sickle Cell Self-Efficacy Scale (6 mos)
  • SCD Health-Related Internalized Stigma Scale (6 mos)
  • Transition Readiness Assessment Questionnaire (TRAQ), (6 mos)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-04-01
Completion: 2029-06-30
Eligibility
Age: 14 Years and older
Sex: ALL
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital Los Angeles
Collaborators: University of Southern California & Children's Hospital Los Angeles (USC-CHLA)
Principal Investigators:
  • Xzania Lee, PhD (PRINCIPAL_INVESTIGATOR) - Children's Hospital Los Angeles
Contact Information
Study Contact:
Xzania Lee, PhD
323.361.4768
xlee@chla.usc.edu
Xzania W Lee, Ph.D.
323-361-4768
xlee@chla.usc.edu
Children's Hospital Los Angeles
Interventions
  • Behavioral: ACT for SCD — Phase I Using a convenience sample, this study examines the feasibility and acceptability of a proposed 6-session ACT group intervention for Black youth with sickle cell disease (SCD), who experience compounded stress due to chronic illness and systemic inequities. A up to 11 youth and up to 11 parents/legal guardians will be enrolled in an ACT group offered via the Division of Adolescent and Young Adult Medicine. Participants will complete assessments at pre-, and post-intervention, and at a 3-month follow-up. Up to 5 of 11 parents/legal guardians and 5 of 11 youth (not required to be dyadic) will also be a part of the studies community advisory board (CAB) to ensure the intervention is culturally and developmentally responsive and grounded in community perspectives. Phase II Over the next 3 years this study will use a community-based participatory action research approach, extending and integrating feedback data collected in Phase I, to conduct a crossover waitlist-control trial.
Study Locations (1 sites)
Children's Hospital Los Angeles, Los Angeles, California 90027 United States
Eligibility Criteria
Youth Participant Inclusion and Exclusion Criteria The inclusion criteria for study participation are Be an adolescent and/or young adult (age 14-21) who has Sickle Cell Disease Willing to enroll in the ACT group jointly provided by the Division of Adolescent and Young Adult Medicine/Department of Hematology and Oncology Participants can be active, waitlisted, or new patients at CHLA Participants must be able to understand and speak English, as the therapy will only be delivered in English Participants must have an English-speaking parent/guardian Able to provide consent/assent An adolescent or young adult that is pregnant is eligible to participate if consent can be obtained Participants must be developmentally typical Have a stable internet connection (via computer, tablet, or phone) with access to a webcam and a private space to engage in a group therapy sessions; Must consent to audio and video recording of initial interview. Must agree to attend 6 weekly ACT group session Youth participants will be asked to become a member of the CAB. To become a CAB member, the youth participant must consent/assent to participation in the ACT intervention. If a CAB member, they must be willing to engage in CAB interviews and meetings. The exclusion criteria are: Prisoners or youth in detention centers Unable to understand or speak English Does not have SCD Clients who are at significant risk for suicide and self-injury will be excluded due to the intense levels of support required to support these individuals which would interfere with study procedures. Adolescents with families that require frequent intervention from the Department of Children and Family Services, are currently experiencing psychosis, or have severe health concerns that will impact study participation or attendance will be excluded.